Utilization of psychopharmacological treatment among patients with newly diagnosed bipolar disorder from 2001 to 2010

Journal of Clinical Psychopharmacology

Volumn 36, Issue 1, 2016, Pages 32-44

  Chang, Chia Ming ^a   Wu, Chi Shin ^b,c   Huang, Ya Wen ^d   Chau, Yeuk Lun ^a   Tsai, Hui Ju ^d,e,f  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antidepressants; Antipsychotics; Benzodiazepines; Bipolar disorder; Mood stabilizers

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROTIZOLAM; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CLOXAZOLAM; ESTAZOLAM; FLUDIAZEPAM; FLURAZEPAM; LAMOTRIGINE; LITHIUM; LORAZEPAM; LORMETAZEPAM; MIDAZOLAM; MOOD STABILIZER; NEUROLEPTIC AGENT; NITRAZEPAM; NORDAZEPAM; OXAZEPAM; OXAZOLAM; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR DISORDER; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; ADOLESCENT; FACTUAL DATABASE; MIDDLE AGED; STATISTICAL MODEL; TAIWAN; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PSYCHOTROPIC DRUGS; TAIWAN; YOUNG ADULT;

EID: 84952981400     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000440     Document Type: Article

References (51)

1. Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67:1-8.
2. Crump C, Sundquist K, Winkleby MA, et al. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013;70:931-939.
3. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings fromthe Global Burden of Disease Study 2010. Lancet. 2013;382:1575-1586.
4. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry. 1997;170:205-228.
5. Bauer M. Review: lithium reduces relapse rates in people with bipolar disorder. Evid Based Ment Health. 2004;7:72.
6. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7(suppl 3):5-69.
7. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23:346-388.
8. Grunze H, Vieta E, Goodwin GM, et al. TheWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14:154-219.
9. Lim PZ, Tunis SL, Edell WS, et al. Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disord. 2001;3:165-173.
10. Dennehy EB, Suppes T, Rush AJ, et al. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychol Med. 2005;35:1695-1706.
11. Fenn HH, Robinson D, Luby V, et al. Trends in pharmacotherapy of Schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry. 1996;153:711-713.
12. Blanco C, Laje G, Olfson M, et al. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry. 2002;159: 1005-1010.
13. Depp C, Ojeda VD, Mastin W, et al. Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001-2004. Psychiatr Serv. 2008;59:1169-1174.
14. Hayes J, Prah P, Nazareth I, et al. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS One. 2011;6:e28725.
15. Alda M, Yatham LN. Is monotherapy as good as polypharmacy in long-term treatment of bipolar disorder? Can J Psychiatry. 2009;54: 719-725.
16. The BALANCE Investigators and Collaborators, Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375:385-395.
17. Yen CF, Chen CS, Ko CH, et al. Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. Psychiatry Clin Neurosci. 2005;59:403-409.
18. Gianfrancesco FD, Rajagopalan K, SajatovicM, et al. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry. 2006;67:222-232.
19. Gonzalez-Pinto A, Mosquera F, Alonso M, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 2006;8:618-624.
20. Swann AC. Approaches to preventing relapse in bipolar disorder: addressing nonadherence and prodromal symptoms. J Clin Psychiatry. 2010;71:e35.
21. Gianfrancesco FD, Sajatovic M, Rajagopalan K, et al. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin Ther. 2008;30:1358-1374.
22. Bai YM, Chang CJ, Tsai SY, et al. Taiwan consensus of pharmacological treatment for bipolar disorder. J Chin Med Assoc. 2013;76:547-556.
23. Wu CS, Chang CM, Chen CY, et al. Association between antidepressants and venous thromboembolism in Taiwan. J Clin Psychopharmacol. 2013;33:31-37.
24. Wu KY, Chang CM, Liang HY, et al. Increased risk of developing dementia in patients with bipolar disorder: a nested matched case-control study. Bipolar Disord. 2013;15:787-794.
25. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo; 2009.
26. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc. 2001;76: 511-527.
27. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
28. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-699.
29. YangM, Barner JC, LawsonKA, et al. Antipsychoticmedication utilization trends among Texas veterans: 1997-2002. Ann Pharmacother. 2008;42: 1229-1238.
30. Baldessarini R, Henk H, Sklar A, et al. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008;59:1175-1183.
31. Levine J, Chengappa KN, Brar JS, et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord. 2000;2:120-130.
32. Brooks JO 3rd, Goldberg JF, Ketter TA, et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry. 2011;72:240-247.
33. Vieta E, Langosch JM, Figueira ML, et al. Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). Int J Neuropsychopharmacol. 2013;16:1719-1732.
34. Hooshmand F, Miller S, Dore J, et al. Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011. J Affect Disord. 2014;155:283-287.
35. Grande I, de Arce R, Jimenez-Arriero MA, et al. Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). Int J Neuropsychopharmacol. 2013;16:513-523.
36. Montoya A, Perez Sanchez Toledo J, Gilaberte I, et al. Patterns of drug treatment for manic episode in the clinical practice. Outcomes of the Spanish sample in the EMBLEM Study. Actas Esp Psiquiatr. 2007;35: 315-322.
37. Lew KH, Chang EY, Rajagopalan K, et al. The effect of medication adherence on health care utilization in bipolar disorder. Manag Care Interface. 2006;19:41-46.
38. Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord. 2013;149: 247-252.
39. Pillarella J, Higashi A, Alexander GC, et al. Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009. Psychiatr Serv. 2012;63:83-86.
40. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs. 2006;20:29-42.
41. Chang HH, Chou CH, Chen PS, et al. High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan. J Affect Disord. 2009;117:124-129.
42. Daban C, ColomF, Sanchez-Moreno J, et al. Clinical correlates of first-episode polarity in bipolar disorder. Compr Psychiatry. 2006;47:433-437.
43. Truman CJ, Goldberg JF, Ghaemi SN, et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry. 2007;68:1472-1479.
44. Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1:351-359.
45. Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report. J Clin Psychiatry. 2010;71:194-200.
46. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159:1-50.
47. Singh T, Rajput M. Misdiagnosis of bipolar disorder. Psychiatry (Edgmont). 2006;3:57-63.
48. Olfson M, Crystal S, Gerhard T, et al. Mental health treatment received by youths in the year before and after a new diagnosis of bipolar disorder. Psychiatr Serv. 2009;60:1098-1106.
49. Stensland MD, Schultz JF, Frytak JR. Diagnosis of unipolar depression following initial identification of bipolar disorder: a common and costly misdiagnosis. J Clin Psychiatry. 2008;69:749-758.
50. Wu CS, Lin YJ, Feng J. Trends in treatment of newly treated schizophrenia-spectrum disorder patients in Taiwan from 1999 to 2006. Pharmacoepidemiol Drug Saf. 2012;21:989-996.
51. Kozma CM, Dickson M, Phillips AL, et al. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherencewith disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7:509-516.